CTCs
Biocept to Refocus CNSide Assay Plans After FDA Feedback Suggests Targeting Narrower Indications
Premium
The company failed in its first bid for breakthrough device designation but has now split out new specific indications for which it is building more persuasive utility data.
Rarecells Raises $13M in Series A Round to Develop Liquid Biopsy Early Cancer Detection Tests
The company is planning to develop circulating tumor cell assays for prostate cancer and acute myeloid leukemia and to launch them in the US.
The Indian liquid biopsy company recently launched its Trublood tests for prostate cancer and pan-cancer detection using circulating tumor cells.
Biocept HER2 Assay Gains Coverage Under Medicare Local Coverage Determination for CTC Tests
Under the LCD, CTC assays, such as Biocept's, will now be covered to guide targeted treatment decisions for patients with breast and other cancers under certain circumstances.
TellBio Raises $5M in Series A Round, Inks Deals With Genetron, ARUP for Liquid Biopsy Platform
The startup's strategic agreements with Genetron Holdings and ARUP Laboratories will accelerate global deployment of its TellDx liquid biopsy platform.